Pharmaxis Ltd
PMXSF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$36M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $36.00 Million |
|---|---|
| Enterprise Value | - |
| Earnings per Share | $-0.01 |
| Beta | 0.27 |
| Outstanding Shares | 1,756,958,751 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | -4.44 |
|---|---|
| PEG | 11.2 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Last Earnings Call
Report Date
August 27, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
February 5, 2027
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Syntara Limited
85 employees
CEO: Gary Jonathan Phillips
Syntara Limited is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies by targeting extracellular matrix dysfunction, primarily through amine oxidase chemistry. Headquartered in Frenchs Forest, Austral...